Circulating Interleukin-15 in Dementia Disorders
| Autor: | Anthousa Tsoutsou, Chryssoula Nikolaou, Michael Rentzos, A. Rombos, Margarita Zoga, George P. Paraskevas, Elisabeth Kapaki, Demetrios Vassilopoulos |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Pathology Enzyme-Linked Immunosorbent Assay Disease Neuropsychological Tests Gastroenterology Statistics Nonparametric Central nervous system disease chemistry.chemical_compound Dementia disorders Immune system Degenerative disease Internal medicine medicine Humans Vascular dementia Aged Aged 80 and over Interleukin-15 Analysis of Variance business.industry Middle Aged medicine.disease Acetylcholinesterase Psychiatry and Mental health chemistry Interleukin 15 Dementia Female Cholinesterase Inhibitors Neurology (clinical) Mental Status Schedule business |
| Zdroj: | The Journal of Neuropsychiatry and Clinical Neurosciences. 19:318-325 |
| ISSN: | 1545-7222 0895-0172 |
| Popis: | The objective of this study was to assess the role of interleukin-15 (IL-15) as a potential marker of immune reactions in patients with Alzheimer's disease and vascular dementia. The authors measured by immunoassay serum IL-15 levels in 20 patients with Alzheimer's disease and 15 patients with vascular dementia and compared them with serum IL-15 levels in 15 healthy subjects. The authors also studied the effect of treatment with acetylcholinesterase inhibitors (AChEI) on serum IL-15 levels. Patients with Alzheimer's disease were found to have significantly lower serum IL-15 levels compared with healthy subjects and patients with vascular dementia. Healthy subjects and patients with vascular dementia did not differ between each other. Age, sex, disease duration, and Mini-Mental State Examination score did not affect IL-15 levels in any of the groups. Treatment with AChEI had no influence on IL-15 concentrations. The findings suggest that IL-15 is not implicated in the pathogenetic mechanisms of Alzheimer's disease and vascular dementia. An immune hyporesponsiveness at some point during disease development may be responsible for the lower levels of IL-15 and other cytokines in Alzheimer's disease patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|